Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 370 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer November 20, 2023 FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF... March 11, 2026 We want every scientist to thrive in cancer research July 28, 2023 EMA Recommends Granting a Marketing Authorisation for Relugolix March 24, 2022 Load more HOT NEWS Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer ESMO Asia Congress 2023, 1-3 December 2023, Singapore Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients... Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery
